---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-030522"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:33:39.813240+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Contineum reports Q1 net loss $14.5M; cash $246.3M through mid-2029

## Summary
- Cash, cash equivalents and marketable securities of $246.3M as of March 31, 2026; runway through mid-2029.
- Net loss of $14.5M vs $16.0M in Q1 2025; R&D expenses down 15% to $11.6M.
- Positive topline Phase 1b data for PIPE-791 in chronic pain (April 30, 2026); safety met and numeric pain improvement.
- Initiated global Phase 2 PROPEL-IPF trial for PIPE-791 in IPF; target 324 patients; enrollment ongoing.
- Johnson & Johnson Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting 124 participants; completion expected June 2026.

## SEC filing metadata
- accession: 0001628280-26-030522
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000162828026030522/0001628280-26-030522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000162828026030522/ctnm-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-030522
- JSON: https://secwatch.observer/filing/0001628280-26-030522.json
- Plain text: https://secwatch.observer/filing/0001628280-26-030522.txt

## Key facts
- Earnings Releases
  Contineum Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $14.5 million.
  - Period: first quarter ended March 31, 2026
  - Net income: Net loss was $14.5 million
  - Result: reported results
  source text: million, a 20 percent increase from the first quarter of 2025. The increase was primarily driven by higher stock-based compensation and employee-related costs. • Net loss was $14.5 million for the three months ended March 31, 2026, as compared to $16.0 million for the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855175/000162828026030522/0001628280-26-030522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.